Katie M. Palmer

1 month ago | autism.einnews.com | Katie M. Palmer

Manage Consent PreferencesThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

1 month ago | statnews.com | Katie M. Palmer

It’s been a year since the federal government clarified that technology tools used in health care shouldn’t discriminate against patients based on protected traits such as age, sex, race, and disability. A lot has changed in that time, including a new president in the White House. But as the May 1 deadline approaches this week, health systems face significant clinical and political uncertainty over how to comply with the rule.

1 month ago | statnews.com | Katie M. Palmer |Elaine Chen

The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies they work with must stop offering copies of the treatments.

1 month ago | statnews.com | Ed Silverman |Katie M. Palmer

Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack — the drugmaker accused two of the companies of engaging in the corporate practice of medicine. To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as GLP-1s.

1 month ago | statnews.com | Katie M. Palmer

RadNet, which runs nearly 400 radiology imaging centers in the United States, wants to put artificial intelligence into breast imaging. Over the last five years, the company has moved aggressively to expand its AI capabilities, deploying the technology for breast cancer screenings at its radiology practices. There, patients can pay $40 out-of-pocket for an algorithm to screen their mammogram, with a double-check if the AI says something different than the human radiologist reading the same scan.